Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

ESMO Open

Supplementary table 1. Patient characteristics

Characteristics		All Patients 150 (%)	Plasma analysis 94 (%)
Age, median (range)	71 (41-93)	150 (100)	94 (100)
Gender	Male	94 (62.7)	61 (64.9)
	Female	56 (37.3)	33 (35.1)
Tumor side	Left	85 (56.7)	45 (47.9)
	Right	65 (43.3)	49 (52.1)
Grading	Well-differentiated	137 (93.2)	88 (93.6)
	Poorly-differentiated	10 (6.8)	6 (6.4)
Stage	I	29 (19.3)	14 (14.9)
	II	66 (44)	41 (43.6)
	III	54 (36)	39 (41.5)
Lymphovascular invasion	Yes	38 (25.9)	31 (32.97)
	No	109 (74.1)	62 (67.02)
Perineural invasion	Yes	30 (20.4)	22 (23.5)
	No	117 (79.6)	71 (75.5)
CEA level at baseline (ng/mL)	3.5	83 (56.5)	51 (54.2)
	> 3,5	64 (43.5)	42 (44.7)
	Unknown		1 (1.1)
MMR status	Proficient	133 (89.4)	84 (89.4)
	Deficient	16 (10.6)	10 (10.6)
Clinicopathologic risk group (Stage II)	Low	38 (58.5)	22 (53.6)
	High	27 (41.5)	19 (46.4)
Adjuvant Chemotherapy	Single-agent fluoropyrimidine	34 (22.5)	23 (24.5%)
	Oxaliplatin-based regimen	21 (13.9)	12 (12.8%)
	No	96 (63.6)	59 (62.8)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

ESMO Open